Celgene Corporation [clinicaltrials_resource:3381cf1e2cb63bb87ed257250cbb040b]
Gordon Bray, MD [clinicaltrials_resource:019c7acad44705011463631c7751180d]Teng Jin Teng Jin Ong, MD [clinicaltrials_resource:022eb9e839c8f70443473668ade4dbec]Irina Khanskaya, MD [clinicaltrials_resource:0257365e84e0dc54c242d8848f68687d]Lei Zhang, M.D [clinicaltrials_resource:05dffc4b4d3f8154e040fb914b018be8]C L Beach, PharmD [clinicaltrials_resource:0653d4bffd587f0d9620eba7fa7fb5e1]Michael Hawkins [clinicaltrials_resource:074c5ebbb90c2d8548ed7c490a564809]Lei Zhang, MD [clinicaltrials_resource:08caee4949bd73cfa22ed206c9eb0008]José Iglesias, MD [clinicaltrials_resource:08e3e3bfbfbc0fae4c00e60a19fb24b3]Teng Jin Teng Jin Ong, MD [clinicaltrials_resource:098f319c76888e93488a4849a246bab9]Sasaki Toru [clinicaltrials_resource:0a7407ef8af95d54f09d5e13767f05fc]C L Beach [clinicaltrials_resource:0c5f7c499cdfee794364d4df131bbf4f]Alfredo Romano, MD [clinicaltrials_resource:0c747d5542ce3598aee3564bc78ab46e]Robert Knight, MD [clinicaltrials_resource:108a5185c3a59f3e039eecc5907c9413]CL Beach, PharmD [clinicaltrials_resource:14949688711ddf5a64a37cb89caa7908]Kenneth Foon, MD [clinicaltrials_resource:151192fb225aa542a144854da7c0f883]William T Smith, MD [clinicaltrials_resource:19dbf796bcde7669c5822481bdf083e5]Maria Palmisano, MD [clinicaltrials_resource:1a16466e41d1c6c7606b92fb9f1cde03]Masaaki Takatoku, MD [clinicaltrials_resource:1a60f9a2c1f9c154ff0f46c724a030cd]Denesh Chitkara, MD [clinicaltrials_resource:1dcedc5e85fcfda080fe699e080a4a59]Michael J Hawkins, M.D. [clinicaltrials_resource:1f093ec05177fbf5c73aa3e6ad2f15ea]Debora Barton, MD [clinicaltrials_resource:21283b8b6ddf009d6f9fd069b2ac66d6]Doug Hough, M.D. [clinicaltrials_resource:224cb816108e343225d1f26ca84e97c1]Abderrahmane Laadem [clinicaltrials_resource:22d64fb45feca85308532f705543664d]Ulf Jungnelius, MD [clinicaltrials_resource:2457d4a7442f3235d09584af132bec42]Jay Backstrom, MD [clinicaltrials_resource:272d42a2ed42d444a66237c7082225f6]Steven Fischkoff [clinicaltrials_resource:27b721d68d6f02e2a03899ec7e1cc3a9]Victoria Manax, MD [clinicaltrials_resource:2815dfa7378bec14adc5392b03dc5af8]Sasaki Toru [clinicaltrials_resource:28235b13e4ea82cbfa18944d7c9bea79]Christian Jacques, MD [clinicaltrials_resource:28e6eda02341a9924876ecc7f7a80bd2]Bouchra Benettaib, MD [clinicaltrials_resource:2c854abd95ad0bec44418be53b5acf94]Jose' Iglesias, MD [clinicaltrials_resource:2d1af97c2c367a5da2ebc8f669b81577]Oliver Kong, MD [clinicaltrials_resource:2d1d19b7d098d10e44a09f82fe0fbf5a]Edward O'Mara, MD [clinicaltrials_resource:302b1d69596349e99423f605a5c3022b]Lars Sternas, MD [clinicaltrials_resource:3112df9417434f0326d8aaf0492fe90f]Maria Palmisano, M.D. [clinicaltrials_resource:321a46d5ddcabe8d364363b22313c99c]Douglas Hough, M.D. [clinicaltrials_resource:322fbd40f58c7991665d88faca463d75]Teng Jin Ong, MD [clinicaltrials_resource:332d2dc6f055b043ec83a29b0c17b425]Barbara Amoroso, MD [clinicaltrials_resource:34f48eda73a26d0bd79c87f200be5bbd]Donald Manning, MD, PhD [clinicaltrials_resource:3546fdf85219bdb9f6ad1dace6bf2224]Robert Gale, MD [clinicaltrials_resource:3581c431b3af18f02b5ee402c1b4313d]
affiliation [clinicaltrials_vocabulary:affiliation]
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer [clinicaltrials:NCT00040391]Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma. [clinicaltrials:NCT00057616]Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy [clinicaltrials:NCT00179608]clinicaltrials:NCT00179621clinicaltrials:NCT00179647clinicaltrials:NCT00179660clinicaltrials:NCT00179673A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer [clinicaltrials:NCT00179686]Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer [clinicaltrials:NCT00179699]Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma [clinicaltrials:NCT00179712]Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma [clinicaltrials:NCT00179725]A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. [clinicaltrials:NCT00179738]A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas [clinicaltrials:NCT00179751]clinicaltrials:NCT00864253clinicaltrials:NCT01146574Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia [clinicaltrials:NCT01351935]clinicaltrials:NCT01476787clinicaltrials:NCT01497093Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males [clinicaltrials:NCT01712828]Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation [clinicaltrials:NCT01915498]
collaborator [clinicaltrials_vocabulary:collaborator]
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome [clinicaltrials:NCT00002127]Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome [clinicaltrials:NCT00002157]A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer [clinicaltrials:NCT00040391]CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma [clinicaltrials:NCT00044018]Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00044382]Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes [clinicaltrials:NCT00045786]A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies [clinicaltrials:NCT00046423]ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer [clinicaltrials:NCT00046514]Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer [clinicaltrials:NCT00046527]Phase 1 Study OF CDC-501 in Patients With Solid Tumors [clinicaltrials:NCT00046735]D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients [clinicaltrials:NCT00047476]A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes [clinicaltrials:NCT00050843]A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma [clinicaltrials:NCT00051116]Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma [clinicaltrials:NCT00055562]clinicaltrials:NCT00056160A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma [clinicaltrials:NCT00057564]Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma. [clinicaltrials:NCT00057616]Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes [clinicaltrials:NCT00064974]clinicaltrials:NCT00065156Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [clinicaltrials:NCT00065351]A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) [clinicaltrials:NCT00067743]clinicaltrials:NCT00071799Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) [clinicaltrials:NCT00072722]Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer [clinicaltrials:NCT00073723]Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas [clinicaltrials:NCT00074646]A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) [clinicaltrials:NCT00091624]Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma [clinicaltrials:NCT00093119]clinicaltrials:NCT00093145A Safety Study of ABI-007 for In-Stent Restenosis [clinicaltrials:NCT00093223]clinicaltrials:NCT00102687Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 [clinicaltrials:NCT00106301]A Research Study for Patients With Prostate Cancer [clinicaltrials:NCT00106418]clinicaltrials:NCT00106431A Research Study for Patients With Metastatic Renal Cell Carcinoma [clinicaltrials:NCT00106613]Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer [clinicaltrials:NCT00107094]clinicaltrials:NCT00109772Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy [clinicaltrials:NCT00120120]clinicaltrials:NCT00124943Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia [clinicaltrials:NCT00126893]clinicaltrials:NCT00140140
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Elisabeth Kueenburg, Medical Project Director Multiple Myeloma, Celgene Corporation [clinicaltrials_resource:0ab8fa69136b76baf922fd96c2b0f162]Robert Knight MD - Vice President, Oncology, Celgene Corporation [clinicaltrials_resource:146c5a33e7c35f193921446917d565ba]Robert Knight MD - VP Hematology, Celgene Corporation [clinicaltrials_resource:15d0faceae51d4ec8b57b60c297a60ab]Victor Sloan MD, VP Clinical R&D, Rheumatology, Celgene Corporation [clinicaltrials_resource:2d071937d079737ea18106e40e9233ba]Jay Backstrom, MD, Vice President, Clinical Development MDS, Celgene Corporation [clinicaltrials_resource:32e5eb0e9a30ce1bfbc44ed95b39b6b6]Anette Nawrocki, Celgene Corporation [clinicaltrials_resource:45aae95dc1933919e2eb226ff1f876fd]Robert Knight, VP Hematology, Celgene Corporation [clinicaltrials_resource:4872ffaeb089269c5f234fead645043b]CL Beach/Senior Director Clinical Research and Development, Celgene Corporation [clinicaltrials_resource:6088e376c06bdf31a445c9c793ebd3c5]Gary Renshaw, MD, Celgene Corporation [clinicaltrials_resource:666c50a9abc63c07e46742054a7802fd]Robert Knight, MD - VP Hematology, Celgene Corporation [clinicaltrials_resource:74305d3a9261388814b222f8064c8ff5]Robert Knight, MD / Vice President, Clinical Research - Hematology, Celgene Corporation [clinicaltrials_resource:79601fcdd07766e78e5031be4dc1d436]Patricia Rohane, MD, Celgene Corporation [clinicaltrials_resource:c3a67788a9b14a684ac5f5ad1078f642]Deborah Ingenito, Celgene Corporation [clinicaltrials_resource:e954559b5be50dcc44bb764323a6f950]Gloria Austin, Study Manager, Celgene Corporation [clinicaltrials_resource:f0045a9be4a5aa558384487a4037f2e8]
organization [clinicaltrials_vocabulary:organization]
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer [clinicaltrials:NCT00040391]CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma [clinicaltrials:NCT00044018]Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00044382]Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes [clinicaltrials:NCT00045786]A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies [clinicaltrials:NCT00046423]ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer [clinicaltrials:NCT00046514]Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer [clinicaltrials:NCT00046527]Phase 1 Study OF CDC-501 in Patients With Solid Tumors [clinicaltrials:NCT00046735]D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients [clinicaltrials:NCT00047476]A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes [clinicaltrials:NCT00050843]A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma [clinicaltrials:NCT00051116]Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma [clinicaltrials:NCT00055562]clinicaltrials:NCT00056160A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma [clinicaltrials:NCT00057564]Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma. [clinicaltrials:NCT00057616]Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes [clinicaltrials:NCT00064974]clinicaltrials:NCT00065156Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [clinicaltrials:NCT00065351]A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) [clinicaltrials:NCT00067743]clinicaltrials:NCT00071799Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) [clinicaltrials:NCT00072722]Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer [clinicaltrials:NCT00073723]Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas [clinicaltrials:NCT00074646]A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) [clinicaltrials:NCT00091624]Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma [clinicaltrials:NCT00093119]clinicaltrials:NCT00093145A Safety Study of ABI-007 for In-Stent Restenosis [clinicaltrials:NCT00093223]clinicaltrials:NCT00102687Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 [clinicaltrials:NCT00106301]A Research Study for Patients With Prostate Cancer [clinicaltrials:NCT00106418]clinicaltrials:NCT00106431A Research Study for Patients With Metastatic Renal Cell Carcinoma [clinicaltrials:NCT00106613]Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer [clinicaltrials:NCT00107094]clinicaltrials:NCT00109772Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy [clinicaltrials:NCT00120120]clinicaltrials:NCT00124943Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia [clinicaltrials:NCT00126893]clinicaltrials:NCT00140140Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy [clinicaltrials:NCT00179608]clinicaltrials:NCT00179621
source [clinicaltrials_vocabulary:source]
Celgene Corporation [clinicaltrials_resource:3381cf1e2cb63bb87ed257250cbb040b]
Bio2RDF identifier
3381cf1e2cb63bb87ed257250cbb040b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3381cf1e2cb63bb87ed257250cbb040b
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:3381cf1e2cb63bb87ed257250cbb040b
title
Celgene Corporation
@en
type
label
Celgene Corporation [clinicaltrials_resource:3381cf1e2cb63bb87ed257250cbb040b]
@en